15407-84-8Relevant academic research and scientific papers
Carvone Schiff base of isoniazid as a novel antitumor agent: Nanoemulsion development and pharmacokinetic evaluation
Bhat, Mashooq A.,Iqbal, Muzaffar,Al-Dhfyan, Abdullah,Shakeel, Faiyaz
, p. 111 - 119 (2015)
In the present study, various nanoemulsion formulations of carvone Schiff base of isoniazid (CSB-INH) were developed by aqueous phase titration method in order to evaluate its anticancer potential. Developed nanoemulsions of CSB-INH were characterized in terms of thermodynamic stability, self-nanoemulsification efficiency, droplet size, polydispersity index (PI), zeta potential (ZP), viscosity, refractive index (RI), % transmittance (% T), surface morphology and in vitro drug release studies. Based on lowest droplet size (19.4 nm), least PI (0.189), lowest viscosity (29.6 cP), optimal values of ZP (- 30.8 mV) & RI (1.341), highest % T (98.9%), highest drug release profile (94.5% after 24 h) and the presence of lowest concentration of Triacetin (12% w/w), formulation N1 was selected for in vitro cytotoxicity and in vivo pharmacokinetic studies. Cytotoxicity studies on human colon cancer cells indicated that CSB-INH in optimized nanoemulsion is around nine times more efficacious than free CSB-INH. Pharmacokinetic studies in Albino rats showed rapid absorption (rate and extent) of CSB-INH from optimized nanoemulsion as compared to its suspension formulation. These results indicated the potential of developed nanoemulsion for oral delivery of CSB-INH for chemoprevention of colon cancer.
